The Russian pharmaceutical industry expands its modern production facilities. A new modern production plant of “Skopinopharm” (affiliated with “Pharmimex”) was open in Ryazan. The opening ceremony was attended by the Government of the Ryazan Region, Oleg Kivaler, Head of the Department of pharmaceutical and medical industry of the Ministry of Trade, Olga Kolotilova, TPP Vice-President, Victor Cherepov, Deputy Director General of the ARPM, Elena Maslovskaya as well as representatives of pharmaceutical companies and professional unions.
Mr. Kovalev noted that the production of the plant is not only important wishing the program of import substitution, but also with its job opportunities for young specialists and graduates from pharmaceutical and medical universities. The modernization of the plant is an important step in accommodation of modern and highly technological productions in Russia within the “Pharma 2020” strategy. Moreover, this project was a successful example of cooperation between the Government of the Ryazan region and the business community. The participants of the event expressed the hope that this project will become a success story for companies that are interested in the long-term presence on the Russian market.
The company is implementing its plan to have a full cycle production of blood and cancer medicines in Russia through the transfer of technologies. The full transition is planned to be completed by 2020. The current capacity of the facility will be able to provide 90% of the current demand for these medicines. Medicines “Octanat” and “Vilate” that are produced by “Skopinopharm” have no analogies in Russia.
Deputy head of the ARPM, Elena Maslovskaya congratulated the company with the new plant facility. “I am glad to note that the current modernization of the “Skopinopharm” plant corresponds to the goals of the Pharma 2020 strategy. Implementation of the strategy is a priority task for the ARPM. We congratulate management of personnel of the new plant and hope that their activity would help to develop the domestic pharma.”